Subscribe To
Intellia to test second crispr therapeutic in hereditary angioedema patients
The New Zealand Medicines and Medical Devices Safety Authority (MEDSAFE) has signed off Intellia Therapeutics Inc's (NASDAQ: NTLA) Phase 1/2 study ...
October 6, 2021, 8:29 am
Intellia to test second crispr therapeutic in hereditary angioedema patients
The New Zealand Medicines and Medical Devices Safety Authority (MEDSAFE) has signed off Intellia Therapeutics Inc's (NASDAQ: NTLA) Phase 1/2 study ...
October 6, 2021, 8:29 am